Showing 1–25 of 131 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Zheng X, Gui X, Yao L, Ma J, He Y, et al.
… the capacity of the short-course approach to identify drug regimens that can shorten the treatment time for tuberculosis.
Feng Z, Miao Y, Peng Y, Sun F, Zhang Y, et al.
…. There is an urgent need to simplify and shorten treatment regimens to reduce interruption and adverse event rates, improve compliance, and reduce costs. Methods ORIENT is a multicenter, randomized controlled, open-label, phase II/III, non-inferiority trial involving DS-TB patie…
Arinaminpathy N, Gomez GB, Sachdeva KS, Rao R, Parmar M, et al.
…re is increasing interest in future, highly-potent 'pan-TB' regimens against tuberculosis (TB), that may be equally effective in both drug-susceptible and rifampicin-resistant (RR) forms of TB. Taking the example of India, the country with the world's largest burden of TB, we sho…
Anaam MS, Alrasheedy AA
…rd 6-month regimen was lower than that with the previous TB regimens. However, more efforts are needed to decrease TB recurrence rates further and achieve a durable cure for TB. In addition, healthcare professionals and TB control programs should consider potential risk factors o…
Reza Yosofi A, Mesic A, Decroo T
…after standardized all-oral short (12 months or less) RR-TB regimens has not yet been systematically reviewed, which is the main objective of this review. Methods This is a systematic review and meta -analysis. PubMed, Web of Science and Google scholar databases were systematical…
John Z Metcalfe, Isabelle R Weir, Kimberly K Scarsi, Alberto Mendoza-Ticona, Samuel Pierre, et al.
**BACKGROUND:** Based on results from preclinical and clinical studies, a five-drug combination of isoniazid, rifapentine, pyrazinamide, ethambutol, and clofazimine was identified with treatment shortening potential for drug-susceptible tuberculosis; the Clo-Fast trial aimed to d…
Zhen Feng, Hailan Wu, Qian Li, Xiaoqiang Zhang, Qingfeng He, et al.
**OBJECTIVES:** High-dose rifamycin (HDR) regimens have demonstrated significant potential in tuberculosis (TB) treatment. This study aims to evaluate the efficacy and safety profile of different HDR regimens. **DESIGN:** Using a systematic review and Bayesian network meta-analy…
Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, et al.
Background Rifapentine-based regimens have potent antimycobacterial activity that may allow for a shorter course in patients with drug-susceptible pulmonary tuberculosis. Methods In an open-label, phase 3, randomized, controlled trial involving persons with newly diagnosed pulmon…
Xu J, Li SY, Almeida DV, Tasneen R, Barnes-Boyle K, et al.
Novel regimens combining bedaquiline and pretomanid with either linezolid (BPaL regimen) or moxifloxacin and pyrazinamide (BPaMZ regimen) shorten the treatment duration needed to cure tuberculosis (TB) in BALB/c mice compared to that of the first-line regimen and have yielded pro…
Saini V, Ammerman NC, Chang YS, Tasneen R, Chaisson RE, et al.
…activity when incorporated into tuberculosis (TB) treatment regimens. We hypothesized that both modifications, i.e., the addition of clofazimine and the replacement of rifampin with high-dose rifapentine, in the first-line regimen for drug-susceptible TB would significantly short…
Carr W, Kurbatova E, Starks A, Goswami N, Allen L, et al.
On May 5, 2021, CDC's Tuberculosis Trials Consortium and the National Institutes of Health (NIH)-sponsored AIDS Clinical Trials Group (ACTG) published results from a randomized controlled trial indicating that a 4-month regimen containing rifapentine (RPT), moxifloxacin (MOX), is…
Bea S, Lee H, Kim JH, Jang SH, Son H, et al.
Background: Adherence to tuberculosis (TB) drugs is one of the key aspects of global TB control, yet there is a lack of epidemiological evidence on the factors influencing adherence to TB drugs. Thus, this study aimed to explore the adherence and factors associated with adherence…
Linda J Harrison, Gustavo E Velásquez, Russell R Kempker, Marjorie Z Imperial, Eric Nuermberger, et al.
…context of drug-resistant TB, offers promise for additional regimens for persons with DS-TB, provided they are sufficiently effective and well-tolerated. We spotlight wave 1 of the RAD-TB platform trial (ACTG A5409, NCT06192160) that will investigate new chemical entities for the…
J Nedelman, M Li, M Olugbosi, R Bruning-Barry, J Ambroso, et al.
…ND and SimpliciTB, clinical trials for drug-susceptible TB, regimens containing pretomanid, pyrazinamide, and other agents (PaZX) had more hepatotoxicity than the standard-of-care regimen of isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE). In Nix-TB and ZeNix, clinical…
Bryant KE, Yuan Y, Engle M, Kurbatova EV, Allen-Blige C, et al.
…on-inferiority phase 3 clinical trial comparing two 4-month regimens to a standard 6 month regimen for treatment of drug-susceptible tuberculosis (TB) among adolescents and adults with a sample size of 2500 participants. Results Central monitoring utilized primary study data in a…
Naidoo A, Dooley KE, Naidoo K, Padayatchi N, Yende-Zuma N, et al.
Introduction Cotreatment of HIV and tuberculosis (TB) reduces morbidity and mortality in coinfected patients. Availability of antiretroviral treatment (ART) drug options, including within drug classes, is important, particularly in high HIV/TB burden low and middle-income countri…
M E Galvis, G E Gao, M M Salerno, M Whitehead, D Juste, et al.
<sec><title>BACKGROUND</title>In February 2022, the U.S. Centers for Disease Control and Prevention (CDC) recommended a 4-month rifapentine-moxifloxacin based regimen (4-HPMZ) for treating drug-susceptible pulmonary TB. We describe 4-HPMZ implementation, treatment outcomes, and r…
Lee H, Bea S, Kim JH, Jeong HE, Jang SH, et al.
…nt drug-susceptible tuberculosis patients who initiated the regimens recommended by the World Health Organization from 2013 to 2018. Adherence was measured using the proportion of days covered (poor [ Results Of 46,818 patients, there were 8% and 11% with poor and moderate adhere…
Ekaterina V Kurbatova, Kelly E Dooley, Wendy Carr, Jason E Stout, Eric L Nuermberger, et al.
…ized controlled phase 2C trial that compares two four-month regimens, BMZ plus rifabutin (Rb) (2BMZRb/2BMRb) or BMZ plus delamanid (D or DLM) (2BMZD/2BMD), with standard 6-months isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE). All drugs are administered seven days per w…
Winston CA, Marks SM, Carr W
We estimated direct costs of a 4-month or 6-month regimen for drug-susceptible pulmonary tuberculosis treatment in the United States. Costs were $23,000 per person treated. Actual treatment costs will vary depending on examination and medication charges, as well as expenses assoc…
Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, et al.
The version of this article originally published was not open access. This article should have been open access. The error has been fixed, and the article is now open access.
Reddy KP, Horsburgh CR, Wood R, Fields NF, Girouard MP, et al.
…osis treatment trials failed to show that some 4-month (4m) regimens were noninferior to conventional 6-month (6m) regimens for a composite clinical outcome. Novel shortened regimens may still have important clinical and economic benefits in populations with high loss to follow-u…
Lopes SR, Marçal M, Fernandes N, Silva F, Barbosa P, et al.
…nes in 2022, on the safety and efficacy of existing and new regimens for drug-susceptible TB (DS-TB) and DR-TB in adults and children. Methods A comprehensive search was performed across three databases for studies published between January 2022 and February 2024, focusing on cur…
Pettit AC, Phillips PPJ, Kurbatova E, Vernon A, Nahid P, et al.
…% to +22.4%]). Fewer AEs were reported in rifapentine-based regimens (15%) than the control regimen (21%). Conclusions In people with HIV-associated DS-PTB with CD4+ counts ≥100 cells/μL on efavirenz-based ART, the 4-month daily rifapentine-moxifloxacin regimen was noninferior to…
Dorman SE, Nahid P, Kurbatova EV, Goldberg SV, Bozeman L, et al.
…trials of tuberculosis treatment have shown that once-daily regimens in which rifampin is replaced by high dose rifapentine have potent antimicrobial activity that may be sufficient to shorten overall treatment duration. Herein we describe the design of an ongoing phase 3 clinica…